Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Big Data’, Device Reprocessing Among FDA's Device Science Goals

This article was originally published in The Gray Sheet

Executive Summary

FDA’s device Center Science Council wants to leverage “big data” and evidence from real-world clinical experience, improve reprocessing of reusable medical devices and enhance use of health information technology and device cybersecurity, among other FY 2016 regulatory science goals.

You may also be interested in...



FDA Says It Is Changing Its Cybersecurity Culture, And Others Should Too

Speaking at the 2015 mHealth Summit, Suzanne Schwartz, the FDA device center's top cybersecurity expert, said the agency is undergoing a cultural shift to better deal with device cybersecurity vulnerabilities and urged manufacturers, security researchers and hospitals to do the same.

CDRH Science Council Explains Its Role, Responsibilities

CDRH's newly formed Center Science Council has a fairly ambitious to-do list, from developing processes for identifying and integrating new science into FDA reviews to designing new programs to improve clinical trials, according to a draft charter released March 31.

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel